Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias-Reference-Cited by-同舟云学术

Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias

Published:2017-06 Issue:7 Volume:26 Page:777-791
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Cerri Silvia¹,Siani Francesca¹,Blandini Fabio¹

Affiliation:

1. Laboratory of Functional Neurochemistry, Center for Research in Neurodegenerative Diseases, C. Mondino National Neurological Institute, Pavia, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2017.1333598

Reference141 articles.

1. Functional changes of the basal ganglia circuitry in Parkinson's disease

2. Pathology of Parkinson’s disease

3. What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them?

4. Epidemiology of Parkinson Disease

5. Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson’s Disease

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Striatal glutamatergic hyperactivity in Parkinson's disease;Neurobiology of Disease;2022-06

2. Synthesis and Biological Evaluation of a Series of Novel 1-(3-((6-Fluoropyridin-3-yl)oxy)propyl)piperazines as Dopamine/Serotonin Receptor Agonists;Pharmaceutical Fronts;2022-03

3. Allosterism and Drug Discovery;Burger's Medicinal Chemistry and Drug Discovery;2021-04-27

4. Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia;Journal of Experimental Pharmacology;2021-04

5. Pharmacological interactions between adenosine A2A receptor antagonists and different neurotransmitter systems;Parkinsonism & Related Disorders;2020-11